Abstract
No public abstract is available from the verified source records.
Peter Caravan
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
European cardiovascular magnetic resonance (EuroCMR) registry-multi national results from 57 centers in 15 countries
10.1186/1532-429x-15-9 · 2013
Efficacy of whole-blood model of gadolinium-based contrast agent relaxivity in predicting vascular MR signal intensity in vivo
10.1002/jmri.29089 · 2024
The nuclear induction experiment
10.1103/physrev.70.474 · 1948
Augmentation of tissue water proton spin-lattice relaxation rates by in vivo addition of paramagnetic ions
1978
Intravenous chelated gadolinium as a contrast agent in NMR imaging of cerebral tumours
10.1016/s0140-6736(84)92852-6 · 1984
Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications
10.1021/cr980440x · 1999
Extracellular MRI contrast agents based on gadolinium
10.1007/3-540-45733-x_1 · 2002
Chemistry of MRI contrast agents: current challenges and new frontiers
10.1021/acs.chemrev.8b00363 · 2019
Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol
10.1007/s00330-001-1242-9 · 2002
MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325
10.1148/radiol.2363040577 · 2005
Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography-multicenter comparative phase III study
10.1148/radiol.2361040148 · 2005
The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates
10.1021/ja017168k · 2002
MS-325: albumin-targeted contrast agent for MR angiography
10.1148/radiology.207.2.9577506 · 1998
Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) as contrast agent for magnetic resonance imaging of the liver: mechanistic studies in animals
10.1097/00004728-199911001-00022 · 1999
A multinuclear MR study of Gd-EOB-DTPA: comprehensive preclinical characterization of an organ specific MRI contrast agent
10.1002/mrm.1910380415 · 1997
Contrast-enhanced magnetic resonance angiography: P792 blood pool agent versus Gd-DOTA in rabbits at 3.0 T versus 1.5 T
10.1097/rli.0b013e318059b58b · 2007
Gadomer-enhanced MR imaging in the detection of microvascular obstruction: alleviation with nicorandil therapy
10.1148/radiol.2362030847 · 2005
Pharmacokinetics and biodistribution of nanoparticles
10.1021/mp800049w · 2008
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease
10.1002/ajh.21656 · 2010
Four-dimensional multiphase steady-state MRI with ferumoxytol enhancement: early multicenter feasibility in pediatric congenital heart disease
10.1148/radiol.2021203696 · 2021
Multicenter safety and practice for off-label diagnostic use of ferumoxytol in MRI
10.1148/radiol.2019190477 · 2019
Quantification of macrophages in high-grade gliomas by using ferumoxytol-enhanced MRI: a pilot study
10.1148/radiol.2018181204 · 2019
Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction
10.1136/heartjnl-2016-311018 · 2017
Synthesis and evaluation of a high relaxivity manganese(II)-based MRI contrast agent
10.1021/ic049559g · 2004
Divalent manganese complexes as potential replacements for gadolinium-based contrast agents
10.1097/rli.0000000000001053 · 2024
Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths
10.1097/01.rli.0000184756.66360.d3 · 2005
Preclinical profile of gadoquatrane: a novel tetrameric, macrocyclic high relaxivity gadolinium-based contrast agent
10.1097/rli.0000000000000889 · 2022
Physicochemical and pharmacokinetic profiles of gadopiclenol: a new macrocyclic gadolinium chelate with high T1 relaxivity: erratum
10.1097/rli.0000000000000632 · 2019
Superparamagnetic iron oxide nanoparticles for MRI
2013
Molecular factors that determine Curie spin relaxation in dysprosium complexes
10.1002/mrm.1277 · 2001
Relaxivity of gadolinium(III) complexes: theory and mechanism
2013
Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil
10.1016/0730-725x(95)00024-b · 1995
Relaxivity of ferumoxytol at 1.5 T and 3.0 T
10.1097/rli.0000000000000434 · 2018
Quantitative dependence of MR signal intensity on tissue concentration of Gd(HP-DO3A) in the nephrectomized rat
10.1016/0730-725x(92)90378-d · 1992
Dependence of MR signal intensity on Gd tissue concentration over a broad dose range
10.1002/mrm.1910220205 · 1991
Evidence for weak protein binding of commercial extracellular gadolinium contrast agents
10.1002/mrm.22214 · 2010
Gd-DTPA relaxivity depends on macromolecular content
10.1002/1522-2594(200011)44:5<665::aid-mrm1>3.0.co;2-m · 2000
Water diffusion and exchange as they influence contrast enhancement
10.1002/jmri.1880070114 · 1997
A unified magnetic resonance imaging pharmacokinetic theory: intravascular and extracellular contrast reagents
10.1002/mrm.20684 · 2005
Nuclear magnetic resonance transverse relaxation times of water protons in skeletal muscle
10.1016/s0006-3495(74)85937-0 · 1974
Incidence of immediate gadolinium contrast media reactions
10.2214/ajr.10.4885 · doi-reference
Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis
10.1148/radiol.2017162740 · doi-reference
Contrast agents for magnetic resonance imaging: safety update
10.1097/00002142-200310000-00007 · doi-reference
High levels of gadolinium deposition in the skin of a patient with normal renal function
10.1097/rli.0000000000000266 · doi-reference
Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates
10.1148/radiol.2018181151 · doi-reference
The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists
10.1039/c8mt00302e · doi-reference
Gadolinium tissue deposition in brain and bone
10.1016/j.mri.2016.08.025 · doi-reference
Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function
10.1097/rli.0000000000000252 · doi-reference
Intracranial gadolinium deposition after contrast-enhanced MR imaging
10.1148/radiol.15150025 · doi-reference
High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration
10.1148/radiol.14140364 · doi-reference
High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material
10.1148/radiol.13131669 · doi-reference
Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents
10.1002/cmmi.100 · doi-reference
Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C
10.1097/rli.0b013e3181852171 · doi-reference
Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the food and drug administration
10.1148/radiol.12112783 · doi-reference
High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent
10.1097/rli.0b013e31815a3407 · doi-reference
Case records of the Massachusetts general hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin
10.1056/nejmcpc0708697 · doi-reference
Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications
10.1002/cmmi.146 · doi-reference
Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis
10.1016/j.jaad.2006.10.047 · doi-reference
Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis
10.1111/j.1365-2133.2007.08335.x · doi-reference
Presumed gadolinium toxicity in subjects with normal renal function: a report of 4 cases
10.1097/rli.0000000000000318 · doi-reference
Self-reported gadolinium toxicity: a survey of patients with chronic symptoms
10.1016/j.mri.2016.05.005 · doi-reference
Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide
10.1007/s00330-006-0495-8 · doi-reference
Gadolinium and nephrogenic systemic fibrosis
10.1038/sj.ki.5002338 · doi-reference
Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?
10.1093/ndt/gfk062 · doi-reference
Nephrogenic systemic fibrosis and gadolinium exposure: association and lessons for idiopathic fibrosing disorders
10.1002/art.22926 · doi-reference
Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium
10.1016/j.yadr.2007.07.002 · doi-reference
Gadolinium-induced fibrosis
10.1146/annurev-med-063014-124936 · doi-reference
Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure
10.1002/art.22925 · doi-reference
Development of specialized magnetic resonance acquisition techniques for human hyperpolarized [(13) C,(15) N(2) ]urea + [1-(13) C]pyruvate simultaneous perfusion and metabolic imaging
10.1002/mrm.29266 · doi-reference
Probing human heart TCA cycle metabolism and response to glucose load using hyperpolarized [2-(13) C]pyruvate MRS
10.1002/nbm.5074 · doi-reference
Noninvasive in vivo assessment of cardiac metabolism in the healthy and diabetic human heart using hyperpolarized (13)C MRI
10.1161/circresaha.119.316260 · doi-reference
Effect of doxorubicin on myocardial bicarbonate production from pyruvate dehydrogenase in women with breast cancer
10.1161/circresaha.120.317970 · doi-reference
Regional quantification of cardiac metabolism with hyperpolarized [1-(13)C]-pyruvate CMR evaluated in an oral glucose challenge
10.1186/s12968-023-00972-7 · doi-reference
MRI application and challenges of hyperpolarized carbon-13 pyruvate in translational and clinical cardiovascular studies: a literature review
10.3390/diagnostics14101035 · doi-reference
Current methods for hyperpolarized [1-(13)C]pyruvate MRI human studies
10.1002/mrm.29875 · doi-reference
Multi-targeted (1)H/(19)F MRI unmasks specific danger patterns for emerging cardiovascular disorders
10.1038/s41467-021-26146-6 · doi-reference
Cardiovascular molecular imaging with fluorine-19 MRI: the road to the clinic
10.1161/circimaging.123.014742 · doi-reference
(19)F MRI in orthotopic cancer model via intratracheal administration of α(ν)β(3)-targeted perfluorocarbon nanoparticles
10.2217/nnm-2018-0051 · doi-reference
Noninvasive imaging of early venous thrombosis by 19F magnetic resonance imaging with targeted perfluorocarbon nanoemulsions
10.1161/circulationaha.114.010962 · doi-reference
Molecular MR imaging of neovascular progression in the Vx2 tumor with αvβ3-targeted paramagnetic nanoparticles
10.1148/radiol.13120789 · doi-reference